NCT07433660Recruiting
WellSpan-THRIVE Cancer QOL Study
WellSpan Study of Tracking Health and Resilience to Improve the Vitality of Individuals Experiencing Cancer [WellSpan-THRIVE]
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences. This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- Feb 2026
- Primary completion date
- Feb 2031
- Lead sponsor
- WellSpan Health
- Diseases
- Ovarian cancer
- NCT number
- NCT07433660
What you commit to
- Study type: Observational
- Planned participants: 1000
- From Feb 2026 to the primary completion date, Feb 2031
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.
- Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.
Age
- Patients with age\<18 years,
Other
- Patients with life expectancy of \<90 days, in the opinion of treating investigator.
Who the study is looking for
- Age 18 years and above
- Primary cancer diagnosis (newly diagnosed within the past 6 months)
- Able to sign informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| WellSpan Medical Oncology & Hematology Coordinator of this site? Confirm its status | Chambersburg | United States | Recruiting |
| WellSpan Ephrata Cancer Center Coordinator of this site? Confirm its status | Ephrata | United States | Recruiting |
| WellSpan Adams Cancer Center Coordinator of this site? Confirm its status | Gettysburg | United States | Recruiting |
| WellSpan Sechler Family Cancer Center Coordinator of this site? Confirm its status | Lebanon | United States | Recruiting |
| WellSpan York Cancer Center Coordinator of this site? Confirm its status | York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.